AI assistant
DBV Technologies — Regulatory Filings 2015
Apr 28, 2015
1248_iss_2015-04-28_2143a1de-b542-46a4-ab46-e53e89c8431c.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Press Release Bagneux, France, Tuesday, April 28, 2015
DBV Technologies Selected to Enter Euronext's Tech 40 Label
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinicalstage specialty biopharmaceutical company, today announced that it has been selected by EnterNext, part of the Euronext exchange, to become a member of the Tech 40 Index tier.
Based on quantitative and qualitative criteria, this Euronext label is awarded on a yearly basis to the top 40 technology companies listed on the SME's* tier of the Euronext exchange.
* PME-ETI
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.
DBV Technologies Contacts
Nathalie Donne Director, Corporate Communication & Business Development Tél. : +33(0)1 55 42 78 72 [email protected]
Susanna Mesa VP Finance, US Investor Relations & Strategy Tél. : +1 917-346-3447 [email protected]
DBV Technologies Media Contacts
Marion Janic Rooney & Associates Tél. : +1-212-223-4017 [email protected]